On Friday, Natco Pharma has said that it has received the USFDA approval for manufacturing a drug for injections that are used in the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkins lymphoma.
Natco Pharma has said in a BSE filing that “We are pleased to announce the final approval of Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA) for generic version of Bendamustine Hydrochloride powder for injection.”
It has further said that it plans to launch this drug on November 1, 2019, or earlier, through its marketing partner Breckenridge Pharmaceutical Inc, in the US market.
